Abstract
The nonnucleoside reverse transcriptase inhibitor etravirine (previous investigational names R165335 and TMC125) is a diarylpyrimidine (DAPY) derivative (see Figure 238.1) and is a potent and highly specific inhibitor of the reverse transcriptase of the human immunodeficiency virus type 1 (HIV-1). In limited studies, it has shown significantly weaker activity against HIV-2.
| Original language | English |
|---|---|
| Title of host publication | Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition |
| Publisher | CRC Press |
| Pages | 3970-3988 |
| ISBN (Electronic) | 9781498747967 |
| ISBN (Print) | 9781498747950 |
| DOIs | |
| Publication status | Published - 2017 |
Publication series
| Name | Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition |
|---|
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Etravirine'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver